Meet
Nicole Meyerson

Associate Principal

Nicole Meyerson supports clients with research and analysis focused on Medicaid, state health policy trends, and the impact of federal health reform.

With experience in state health policy and value-based initiatives, she applies her background to a broad range of client projects.

Prior to joining Avalere, Nicole was a health policy fellow at ML Strategies, researching, analyzing, and authoring briefs to present to clients on Medicaid 1115 waivers. Nicole also represented the firm and clients at Congressional hearings, stakeholder meetings, and at MedPAC and MACPAC public meetings. Nicole holds an MPH in health policy from the George Washington University’s Milken Institute School of Public Health and BA in human development and public health from Oregon State University.

Authored Content

April 1, 2025 | Insights & Analysis > Coverage and Payment

Expiration of Enhanced Tax Credits Would Impact 18M Americans
If the ACA marketplace enhanced premium tax credits are made permanent, nearly 5 million people ages 50–64 will be eligible to receive premium subsidies in 2026.
September 24, 2024 | Webinars > Regulatory Strategy and FDA Policy

Webinar: Exploring RNA-Based Therapies: Innovations and Impact
Join us for a webinar exploring the RNA-Based Therapy landscape.
August 27, 2024 | Insights & Analysis > Cell and Gene Therapy

Examining Variation in Gene Therapy Access Across States
State Medicaid programs take a range of approaches to gene therapy coverage, management, and reimbursement.
August 26, 2024 | Insights & Analysis > Coverage and Payment

125,000 in MS Could Gain Medicaid Coverage Through Expansion
If Mississippi expands Medicaid to 138% federal poverty level, Avalere estimates 125,000 uninsured individuals, ages 19-64, could gain coverage in 2025.
June 3, 2024 | Insights & Analysis > Regulatory Strategy and FDA Policy

Avalere White Paper: RNA-Based Therapy Outlook
A white paper explores the RNA-based therapy pipeline and how FDA classifications can influence product development, commercialization, and patient access.
February 23, 2024 | Videos > Federal and State Policy

Video: How Policies Shape the Rare Disease Treatment Landscape
In this installment of our 2024 Trends Influencing Rare Disease series, Avalere experts explore policies shaping rare disease drug development and access.
February 5, 2024 | Insights & Analysis > Cell and Gene Therapy

Understanding the CMS Cell and Gene Therapy Access Model
The CGT Access Model will allow CMS to negotiate outcomes-based agreements on behalf of state Medicaid programs for CGTs, beginning with sickle cell disease.
December 19, 2023 | Insights & Analysis > Federal and State Policy

Proposed Changes to Best Price Could Shift Market Dynamics for Stakeholders
The MDRP proposed rule's Best Price "stacking' provision has direct and indirect impacts on Medicaid rebate liability across drug classes.
November 14, 2023 | Insights & Analysis > Federal and State Policy

Medicare HI Trust Fund Solvency Assuming MA Utilization
The Hospital Insurance Trust Fund would remain solvent until 2048 if FFS utilization levels were similar to Medicare Advantage utilization levels.
October 20, 2023 | Insights & Analysis > Federal and State Policy

CBO Considers Cost of Increasing Anti-Obesity Medication Use
Insurance coverage of anti-obesity medications is increasing, but patient access under Medicare remains uncertain.
July 26, 2023 | Insights & Analysis > Drug Pricing and Affordability

CMS Best Price Discount Stacking Proposal May Trigger AMP Cap
Requiring manufacturers to stack all discounts provided through the supply chain could increase Medicaid rebate liability and complicate rebate dynamics.
July 6, 2022 | Insights & Analysis > Drug Pricing and Affordability

The Rare Disease Market: Policy Changes and Coverage Trends
Changes to rare disease policies and payers’ approaches to coverage could have significant impacts on product development, patient access, and reimbursement.
June 27, 2022 | Insights & Analysis > Drug Pricing and Affordability

Value-Based Arrangement Pricing Flexibilities Will Take Effect July 1
Starting July 1, manufacturers can report multiple best prices for some value-based arrangements, which may encourage broader use of innovative contracting.
July 13, 2021 | Insights & Analysis > Drug Pricing and Affordability

Series of Changes to Drug Pricing Metrics Will Interact in Coming Years
The intersection of upcoming changes to drug pricing metrics will require new methods of calculating and reporting government pricing with implications for net pricing and contracting strategies.
September 14, 2020 | Insights & Analysis > Federal and State Policy

Fall Medicaid Outlook: Key Events to Watch
Medicaid will continue to experience considerable changes at the state and federal levels, both in terms of beneficiary demographics and the payer landscape. Stakeholders should consider how upcoming elections, policy proposals, and COVID-19 will impact benefits and payer dynamics.
May 20, 2020 | Insights & Analysis > Federal and State Policy

Manufacturers Must Navigate Evolving State Approaches to Medicaid Drug Benefit Management
As control of the Medicaid drug benefit continues to shift from managed care organizations to states, manufacturers should understand unique benefit dynamics in each state, particularly as Medicaid enrollment is likely to increase amid the COVID-19 pandemic.